Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2006 Apr 7;312(5770):117-21.
doi: 10.1126/science.1124287.

Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome

Jennifer P Habashi  1 , Daniel P Judge, Tammy M Holm, Ronald D Cohn, Bart L Loeys, Timothy K Cooper, Loretha Myers, Erin C Klein, Guosheng Liu, Carla Calvi, Megan Podowski, Enid R Neptune, Marc K Halushka, Djahida Bedja, Kathleen Gabrielson, Daniel B Rifkin, Luca Carta, Francesco Ramirez, David L Huso, Harry C Dietz
Affiliations

Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome

Jennifer P Habashi et al. Science. .

Abstract

Aortic aneurysm and dissection are manifestations of Marfan syndrome (MFS), a disorder caused by mutations in the gene that encodes fibrillin-1. Selected manifestations of MFS reflect excessive signaling by the transforming growth factor-beta (TGF-beta) family of cytokines. We show that aortic aneurysm in a mouse model of MFS is associated with increased TGF-beta signaling and can be prevented by TGF-beta antagonists such as TGF-beta-neutralizing antibody or the angiotensin II type 1 receptor (AT1) blocker, losartan. AT1 antagonism also partially reversed noncardiovascular manifestations of MFS, including impaired alveolar septation. These data suggest that losartan, a drug already in clinical use for hypertension, merits investigation as a therapeutic strategy for patients with MFS and has the potential to prevent the major life-threatening manifestation of this disorder.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Postnatal treatment with TGF-β NAb. (A to H) Characterization of the ascending aorta in untreated wild-type mice [(A) and (E)] and Fbn1C1039G/+ mice treated with placebo [(B) and (F)], 1 mg/kg TGF-β NAb [(C) and (G)], and 10 mg/kg TGF-β NAb [(D) and (H)]. In (A) to (D), Verhoeff's–van Gieson (VVG) stain reveals diffuse disruption of elastic fiber architecture and thickening of the aortic media (delineated by arrows) in placebo-treated Fbn1C1039G/+ mice (B) relative to the normal elastic fiber architecture observed in wild-type mice (A). Improvement in both parameters is seen in NAb-treated Fbn1C1039G/+ mice [(C) and (D)]. Scale bars, 40 μm. In (E) to (H), immunohisto-chemistry (IH) reveals nuclear pSmad2, a marker for TGF-β signaling (arrows indicate representative positive nuclei). Increased pSmad2 is observed in the placebo-treated Fbn1C1039G/+ mice (F) relative to wild-type mice (E). Normalized pSmad2 staining is observed in the NAb-treated Fbn1C1039G/+ mice [(G) and (H)]. Scale bars, 50 μm. (I) Average aortic root growth (±SD) measured by echocardiogram over the 2-month treatment period. Note the reduced rate of growth in the NAb-treated mice relative to the placebo-treated Fbn1C1039G/+ mice. *P < 0.0001, **P < 0.03, †P = 0.11, ‡P = 1.0. (J) Average thickness (±SD) of the proximal ascending aortic media of four representative sections measured by an observer blinded to genotype and treatment arm. Note full normalization of thickness in NAb-treated Fbn1C1039G/+ mice. *P < 0.01, †P = 0.91, ‡P = 0.38. (K) Average aortic wall architecture score (±SD) of the proximal ascending aorta. Three separate observers who were blinded to genotype and treatment arm graded elastic fiber architecture in four representative areas on a scale from 1 (completely intact elastic lamellae) to 4 (extensive fragmentation). Note the improvement in NAb-treated Fbn1C1039G/+ mice. *P < 0.007, **P < 0.0001, ***P < 0.001, †P = 0.21.
Fig. 2
Fig. 2
Prenatal treatment with losartan and propranolol. (A to D) VVG staining highlights intact elastic fiber architecture and normal ascending aortic wall thickness (arrows) in wild-type mice (A) and losartan-treated Fbn1C1039G/+ mice (D). Marked elastic fiber disruption and wall thickening is apparent in the placebo- and propranolol-treated Fbn1C1039G/+ mice [(B) and (C).] Scale bars, 40 μm. (E) Average aortic wall thickness (±SD) after 10 months of treatment. Note full normalization of wall thickness in losartan-treated Fbn1C1039G/+ mice relative to mice that received placebo or propranolol treatment. *P < 0.0001, **P < 0.002, †P = 0.24, ‡P = 0.19. (F) Average aortic wall architecture score (±SD) after treatment. Note the improvement in losartan-treated Fbn1C1039G/+ mice. *P < 0.02, **P < 0.0001, †P = 0.16.
Fig. 3
Fig. 3
Postnatal treatment with losartan and propranolol. (A to H) VVG staining [(A) to (D)] and pSmad2 immunostaining [(E) to (H)] of aortic wall. Elastic lamellae are intact and aortic media is of normal thickness in the wild-type (A) and losartan-treated Fbn1C1039G/+ mice (D). Placebo-and propranolol-treated Fbn1 C1039G/+ mice [(B) and (C)] have diffuse fragmentation of elastic fibers and thickening of the aortic media (arrows). Scale bars, 50 μm. Nuclear pSmad2 staining is decreased in the aortic media of wild-type (E) and losartan-treated Fbn1C1039G/+ mice (H). Marked increase in nuclear staining for pSmad2 (representative positive cells denoted by arrowheads) is seen in the Fbn1C1039G/+ mice treated with placebo (F) and propranolol (G). Scale bars, 40 μm. (I) Average aortic root growth (±SD) during the 6 months of treatment. Note that aortic root growth in Fbn1C1039G/+ mice treated with propranolol is less than that with placebo, yet remains greater than that seen in wild-type mice. Losartan treatment normalizes growth rate. *P < 0.0001, **P < 0.001, ***P < 0.02, †P = 0.55. (J) Average aortic wall thickness (±SD). Aortic wall thickness in losartan-treated Fbn1C1039G/+ mice is reduced relative to placebo- and propranolol-treated mice and is indistinguishable from that seen in wild-type mice. *P < 0.002, **P < 0.0001, ***P < 0.05, †P = 0.67, ‡P = 0.17. (K) Average aortic wall architecture (±SD). Note full normalization achieved with losartan treatment. *P < 0.002, **P < 0.0001, ***P < 0.05, †P = 0.20, ‡P = 0.47.
Fig. 4
Fig. 4
Postnatal losartan treatment of lung disease in Fbn1C1039G/+ mice. Histologic analysis of lung in wild-type mice (A) shows normal airspace caliber. Fbn1C1039G/+ mice treated with placebo (B) show diffuse distal airspace widening (example delineated with arrows). Distal airspace caliber is reduced in Fbn1C1039G/+ mice treated with losartan (C). Scale bars, 500 μm. (D) Average mean linear intercept, a marker of airspace caliber, is greater for placebo-treated Fbn1C1039G/+ mice than for untreated wild-type and losartan-treated Fbn1C1039G/+ mice. *P < 0.01, **P < 0.001.
See this image and copyright information in PMC

Comment in

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Dietz HC, et al. Nature. 1991;352:337. - PubMed
    1. Sakai LY, Keene DR, Glanville RW, Bachinger HP. J. Biol. Chem. 1991;266:14763. - PubMed
    1. Visconti RP, Barth JL, Keeley FW, Little CD. Matrix Biol. 2003;22:109. - PubMed
    1. Isogai Z, et al. J. Biol. Chem. 2003;278:2750. - PubMed
    1. Neptune ER, et al. Nat. Genet. 2003;33:407. - PubMed

Publication types

MeSH terms